ArticleFrontiers in medicine2025
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Specific Probiotic Strains in Subtypes of Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Recent advances in the positive role ofFrontiers in immunology · 2026Review
- Salt sensitivity potentiates high-salt diet-induced intestinal barrier disruption and gut microbiome dysbiosis in rats.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Probiotic-based strategies are increasingly being explored for IBS management, with growing interest in strain-specific applications. Objective: This study aimed to evaluate the clinical efficacy of Methods: A total of 51 IBS patients were recruited and stratified into two groups: IBS-D patients received Results: Both probiotic formulations significantly reduced IBS-SSS scores, particularly improving bloating, abdominal pain, and overall quality of life. The impact of treatment was independent of age, though greater improvements in bloating and life interference were observed in older IBS-C patients. A direct correlation between baseline symptom severity and symptom reduction was identified, suggesting higher efficacy in more severe cases. Conclusion: This study supports the use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.